Search Results - "Pirie, C.M."

Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model by Ke, H.Z., Chen, H.K., Simmons, H.A., Qi, H., Crawford, D.T., Pirie, C.M., Chidsey-Frink, K.L., Ma, Y.F., Jee, W.S.S., Thompson, D.D.

“…The purpose of this study was to compare the effects of droloxifene (DRO), tamoxifen (TAM), and 17α-ethynyl estradiol (EE) on bone mineral density, bone…”
Get full text

FDA guidelines and animal models for osteoporosis by THOMPSON, D. D, SIMMONS, H. A, PIRIE, C. M, KE, H. Z

“…The recent FDA Guidelines For Preclinical and Clinical Evaluation of Agents Used in the Treatment or Prevention of Postmenopausal Osteoporosis (1994) delineate…”
Get full text

Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia by Ke, H.Z, Shen, V.W, Qi, H, Crawford, D.T, Wu, D.D, Liang, X.G, Chidsey-Frink, K.L, Pirie, C.M, Simmons, H.A, Thompson, D.D

“…It is well documented that prostaglandin E2 (PGE2) has the ability to stimulate bone formation, improve bone structure, and increase bone mass in intact or…”
Get full text

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats by KE, H. Z, CHEN, H. K, QI, H, PIRIE, C. M, SIMMONS, H. A, MA, Y. F, JEE, W. S. S, THOMPSON, D. D

“…The purpose of this study was to determine the efficacy of droloxifene (DRO), an estrogen antagonist/agonist, in preventing ovariectomy (OVX)-induced lumbar…”
Get full text

Droloxifene does not blunt bone anabolic effects of prostaglandin E 2, but maintains prostaglandin E 2-restored bone in aged, ovariectomized rats by Ke, H.Z, Crawford, D.T, Qi, H, Pirie, C.M, Simmons, H.A, Chidsey-Frink, K.L, Chen, H.K, Jee, W.S.S, Thompson, D.D

“…Droloxifene (DRO) is a selective estrogen receptor modulator that prevents bone loss by inhibition of bone turnover associated with estrogen deficiency in both…”
Get full text

CP-336,156, a new estrogen agonist/antagonist, inhibits bone turnover and prevents bone loss in ovariectomized rats by Ke, H.Z., Qi, H., Crawford, D.T., Chidsey-Frink, K.L., Simmons, H.A., Pirie, C.M., Thompson, D.D.

Get full text

Longitudinal and cross-sectional characterization of long-term skeletal effects of aging and orchidectomy in the male rat by Ke, H.Z., Qi, H., Crawford, D.T., Pirie, C.M., Simmons, H.A., Thompson, D.D.

Get full text

Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats by KE, H. Z, CRAWFORD, D. T, QI, H, PIRIE, C. M, SIMMONS, H. A, CHIDSEY-FRINK, K. L, CHEN, H. K, JEE, W. S. S, THOMPSON, D. D

“…Droloxifene (DRO) is a selective estrogen receptor modulator that prevents bone loss by inhibition of bone turnover associated with estrogen deficiency in both…”
Get full text

Droloxifene inhibits cortical bone turnover associated with estrogen deficiency in rats by CHEN, H. K, KE, H. Z, LIN, C. H, MA, Y. F, QI, H, CRAWFORD, D. T, PIRIE, C. M, SIMMONS, H. A, JEE, W. S. S, THOMPSON, D. D

“…Droloxifene (DRO), an estrogen antagonist/agonist, has been shown to possess estrogen-like effects in inhibiting bone turnover leading to cancellous bone loss…”
Get full text